JP2014532060A - 癌を治療するためのピロロピリミジン化合物 - Google Patents
癌を治療するためのピロロピリミジン化合物 Download PDFInfo
- Publication number
- JP2014532060A JP2014532060A JP2014534626A JP2014534626A JP2014532060A JP 2014532060 A JP2014532060 A JP 2014532060A JP 2014534626 A JP2014534626 A JP 2014534626A JP 2014534626 A JP2014534626 A JP 2014534626A JP 2014532060 A JP2014532060 A JP 2014532060A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- group
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*1CCCCC1 Chemical compound C*1CCCCC1 0.000 description 6
- YJGXBNHDONVPMN-UHFFFAOYSA-N CCCCNc(nc1)nc2c1[nH]cc2 Chemical compound CCCCNc(nc1)nc2c1[nH]cc2 YJGXBNHDONVPMN-UHFFFAOYSA-N 0.000 description 1
- VZMAPRAHABNJSB-QGZVFWFLSA-N CCCC[C@@H](CC)c(c1nc(NCCCC)ncc11)c[n]1-c(cc1)ccc1F Chemical compound CCCC[C@@H](CC)c(c1nc(NCCCC)ncc11)c[n]1-c(cc1)ccc1F VZMAPRAHABNJSB-QGZVFWFLSA-N 0.000 description 1
- WRWPPGUCZBJXKX-UHFFFAOYSA-N Cc(cc1)ccc1F Chemical compound Cc(cc1)ccc1F WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- LWPPASWKWXDDFK-UHFFFAOYSA-N Clc1ncc2[nH]ccc2n1 Chemical compound Clc1ncc2[nH]ccc2n1 LWPPASWKWXDDFK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161542392P | 2011-10-03 | 2011-10-03 | |
US61/542,392 | 2011-10-03 | ||
US201161547183P | 2011-10-14 | 2011-10-14 | |
US61/547,183 | 2011-10-14 | ||
PCT/US2012/058298 WO2013052417A1 (en) | 2011-10-03 | 2012-10-01 | Pyrrolopyrimidine compounds for the treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016255095A Division JP6316925B2 (ja) | 2011-10-03 | 2016-12-28 | 癌を治療するためのピロロピリミジン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014532060A true JP2014532060A (ja) | 2014-12-04 |
JP2014532060A5 JP2014532060A5 (pt-PT) | 2016-03-03 |
Family
ID=48044101
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014534626A Pending JP2014532060A (ja) | 2011-10-03 | 2012-10-01 | 癌を治療するためのピロロピリミジン化合物 |
JP2016255095A Active JP6316925B2 (ja) | 2011-10-03 | 2016-12-28 | 癌を治療するためのピロロピリミジン化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016255095A Active JP6316925B2 (ja) | 2011-10-03 | 2016-12-28 | 癌を治療するためのピロロピリミジン化合物 |
Country Status (14)
Country | Link |
---|---|
US (3) | US9273056B2 (pt-PT) |
EP (1) | EP2763988B1 (pt-PT) |
JP (2) | JP2014532060A (pt-PT) |
KR (1) | KR102063098B1 (pt-PT) |
CN (1) | CN103958510B (pt-PT) |
AU (1) | AU2012318896B2 (pt-PT) |
BR (1) | BR112014007788A2 (pt-PT) |
CA (1) | CA2850617A1 (pt-PT) |
ES (1) | ES2650630T3 (pt-PT) |
HK (1) | HK1201256A1 (pt-PT) |
IL (1) | IL231835A0 (pt-PT) |
MX (1) | MX2014004086A (pt-PT) |
RU (1) | RU2631655C2 (pt-PT) |
WO (1) | WO2013052417A1 (pt-PT) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018514559A (ja) * | 2015-04-29 | 2018-06-07 | シアメン ユニヴァーシティー | ピリミドピロール類化合物、その調製方法、医薬用組成物及びその応用 |
KR20190111008A (ko) * | 2016-09-16 | 2019-10-01 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호작용의 억제제 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2763988B1 (en) | 2011-10-03 | 2017-09-20 | The University of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
EP3129377A4 (en) * | 2014-04-11 | 2017-12-20 | The University of North Carolina at Chapel Hill | Mertk-specific pyrimidine compounds |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
WO2017062797A1 (en) * | 2015-10-07 | 2017-04-13 | The University Of North Carolina At Chapel Hill | The methods for treatment of tumors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
PE20190175A1 (es) | 2016-03-28 | 2019-02-01 | Incyte Corp | Compuestos de pirrolotriazina como inhibidores de tam |
WO2018094227A1 (en) | 2016-11-17 | 2018-05-24 | The University Of North Carolina At Chapel Hill | Alkyl pyrrolopyrimidine analogs and methods of making and using same |
KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
WO2019113190A1 (en) | 2017-12-07 | 2019-06-13 | Array Biopharma Inc. | Bicyclic fused pyridine compounds as inhibitors of tam kinases |
KR20200104336A (ko) * | 2017-12-28 | 2020-09-03 | 재단법인 생물기술개발중심 | 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물 |
AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
KR102163494B1 (ko) * | 2018-10-26 | 2020-10-08 | 한국과학기술연구원 | 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체 |
CN114127071B (zh) * | 2019-04-02 | 2024-03-22 | 梅里克斯股份有限公司 | 激酶抑制剂的多晶型、含有该化合物的药物组合物、制备方法、及应用 |
CN112043710A (zh) * | 2020-09-28 | 2020-12-08 | 广州智睿医药科技有限公司 | 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 |
CN115073469B (zh) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049706A1 (en) * | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
US20070225306A1 (en) * | 2004-02-14 | 2007-09-27 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
US20080267887A1 (en) * | 2004-10-05 | 2008-10-30 | Neurogen Corporation | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds |
WO2009062112A2 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
TWI238824B (en) * | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
DE60228103D1 (de) | 2001-10-02 | 2008-09-18 | Smithkline Beecham Corp | Chemische verbindungen |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
US7589086B2 (en) | 2003-05-28 | 2009-09-15 | Universita Degli Studi Di Siena | Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB0320728D0 (en) | 2003-09-04 | 2003-10-08 | Kilminster Shaun | Test |
WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
EP2260849A1 (en) | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
EP1749827A4 (en) | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | ANTITUMOR AGENTS |
EP1732541A4 (en) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
TW200626574A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007044426A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2007067730A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
WO2007075554A2 (en) * | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
JP5681855B2 (ja) | 2007-10-12 | 2015-03-11 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
WO2010030781A2 (en) | 2008-09-10 | 2010-03-18 | Numed International, Inc. | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
GB0819105D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
US8765727B2 (en) | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
TW201102391A (en) * | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
AR076550A1 (es) | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
US8840889B2 (en) | 2009-08-13 | 2014-09-23 | The Johns Hopkins University | Methods of modulating immune function |
EP2475668A1 (en) | 2009-09-10 | 2012-07-18 | Novartis AG | Ether derivatives of bicyclic heteroaryls |
WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
EP2640392B1 (en) | 2010-11-18 | 2015-01-07 | Kasina Laila Innova Pharmaceuticals Private Ltd. | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
BR112014006840A2 (pt) * | 2011-09-22 | 2017-04-04 | Pfizer | derivados de pirrolopirimidina e purina |
EP2763988B1 (en) | 2011-10-03 | 2017-09-20 | The University of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
US20160015808A1 (en) | 2012-02-21 | 2016-01-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tam receptors as virus entry cofactors |
IN2012CH01573A (pt-PT) | 2012-04-20 | 2015-07-10 | Advinus Therapeutics Ltd | |
MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
EP3129377A4 (en) | 2014-04-11 | 2017-12-20 | The University of North Carolina at Chapel Hill | Mertk-specific pyrimidine compounds |
-
2012
- 2012-10-01 EP EP12839069.7A patent/EP2763988B1/en active Active
- 2012-10-01 JP JP2014534626A patent/JP2014532060A/ja active Pending
- 2012-10-01 CN CN201280056825.4A patent/CN103958510B/zh active Active
- 2012-10-01 BR BR112014007788A patent/BR112014007788A2/pt not_active IP Right Cessation
- 2012-10-01 ES ES12839069.7T patent/ES2650630T3/es active Active
- 2012-10-01 MX MX2014004086A patent/MX2014004086A/es unknown
- 2012-10-01 CA CA2850617A patent/CA2850617A1/en not_active Abandoned
- 2012-10-01 US US14/348,805 patent/US9273056B2/en active Active
- 2012-10-01 AU AU2012318896A patent/AU2012318896B2/en active Active
- 2012-10-01 RU RU2014115847A patent/RU2631655C2/ru active
- 2012-10-01 KR KR1020147010156A patent/KR102063098B1/ko active IP Right Grant
- 2012-10-01 WO PCT/US2012/058298 patent/WO2013052417A1/en active Application Filing
-
2014
- 2014-03-31 IL IL231835A patent/IL231835A0/en unknown
-
2015
- 2015-02-13 HK HK15101648.7A patent/HK1201256A1/xx unknown
-
2016
- 2016-02-03 US US15/014,573 patent/US9795606B2/en active Active
- 2016-12-28 JP JP2016255095A patent/JP6316925B2/ja active Active
-
2017
- 2017-10-23 US US15/790,700 patent/US10179133B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049706A1 (en) * | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
US20070225306A1 (en) * | 2004-02-14 | 2007-09-27 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
US20080267887A1 (en) * | 2004-10-05 | 2008-10-30 | Neurogen Corporation | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds |
US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
WO2009062112A2 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
Non-Patent Citations (1)
Title |
---|
JPN6016005921; Bioorganic & Medicinal Chemistry Letters Vol.20, No.1, 2010, p.334-337 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018514559A (ja) * | 2015-04-29 | 2018-06-07 | シアメン ユニヴァーシティー | ピリミドピロール類化合物、その調製方法、医薬用組成物及びその応用 |
KR20190111008A (ko) * | 2016-09-16 | 2019-10-01 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호작용의 억제제 |
JP2019529421A (ja) * | 2016-09-16 | 2019-10-17 | ヴァイティー ファーマシューティカルズ,エルエルシー | menin−MLL相互作用の阻害剤 |
JP2022189853A (ja) * | 2016-09-16 | 2022-12-22 | ヴァイティー ファーマシューティカルズ,エルエルシー | menin-MLL相互作用の阻害剤 |
KR102536029B1 (ko) | 2016-09-16 | 2023-05-23 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호작용의 억제제 |
Also Published As
Publication number | Publication date |
---|---|
WO2013052417A1 (en) | 2013-04-11 |
KR102063098B1 (ko) | 2020-01-08 |
JP2017101043A (ja) | 2017-06-08 |
IL231835A0 (en) | 2014-05-28 |
MX2014004086A (es) | 2014-09-22 |
RU2631655C2 (ru) | 2017-09-26 |
CN103958510B (zh) | 2016-10-19 |
US9795606B2 (en) | 2017-10-24 |
CN103958510A (zh) | 2014-07-30 |
CA2850617A1 (en) | 2013-04-11 |
HK1201256A1 (en) | 2015-08-28 |
US20140243315A1 (en) | 2014-08-28 |
BR112014007788A2 (pt) | 2017-04-18 |
RU2014115847A (ru) | 2015-11-10 |
JP6316925B2 (ja) | 2018-04-25 |
EP2763988A1 (en) | 2014-08-13 |
US20180104247A1 (en) | 2018-04-19 |
EP2763988B1 (en) | 2017-09-20 |
ES2650630T3 (es) | 2018-01-19 |
AU2012318896A1 (en) | 2014-05-22 |
US20160151372A1 (en) | 2016-06-02 |
KR20140095471A (ko) | 2014-08-01 |
US10179133B2 (en) | 2019-01-15 |
EP2763988A4 (en) | 2015-06-03 |
AU2012318896B2 (en) | 2017-03-02 |
US9273056B2 (en) | 2016-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6316925B2 (ja) | 癌を治療するためのピロロピリミジン化合物 | |
US9744172B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
AU2013266438B2 (en) | Pyrimidine compounds for the treatment of cancer | |
US9771330B2 (en) | Pyrimidine compounds for the treatment of cancer | |
US9562047B2 (en) | Pyrazolopyrimidine compounds for the treatment of cancer | |
US20080319044A1 (en) | Compounds and Methods of Use Thereof | |
US20080269204A1 (en) | Compounds and Methods of Use Thereof | |
JP2008518923A (ja) | 化合物およびその使用方法 | |
US8551976B2 (en) | Prochelators for inhibiting metal-promoted oxidative stress | |
WO2006063010A2 (en) | Compounds and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160108 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20160108 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160902 |